Research
Hormonal
1-year treatment persistence among individuals without diabetes initiating high-potency, weight loss-indicated GLP-1RA products increased from 33.2% in 2021 to 60.9% in 1H 2024.
Practitioners should note the significant improvement in treatment persistence, which may indicate better patient adherence and management strategies.
StrongSupportsmedium confidence
1-year treatment persistence has nearly doubled from 33.2% in 2021 to 60.9% in 1H 2024.
Why this rating
Based on the cohort study design with a large sample size.
Source
Trends in 1-year persistence and adherence among initiators of high-potency, weight loss–indicated glucagon-like peptide 1 receptor agonists
Landon Marshall et al. · Journal of Managed Care & Specialty Pharmacy · 2026
cohort · n=62650Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →